Get the Stockscreener App
2.03
3.57%
0.07
Cardiff Oncology Inc stock is traded at $2.03, with a volume of 1.23M.
It is up +3.57% in the last 24 hours and down -8.97% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$1.96
Open:
$1.96
24h Volume:
1.23M
Relative Volume:
1.41
Market Cap:
$136.74M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.1828
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-4.69%
1M Performance:
-8.97%
6M Performance:
-30.00%
1Y Performance:
-18.80%
1-Day Range:
$1.90
$2.04
1-Week Range:
$1.90
$2.165
52-Week Range:
$1.90
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.03 | 132.03M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Can Cardiff Oncology Inc. (XE7C) stock hit consensus price targetsJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Cardiff Oncology Inc. forming a reversal pattern2025 Technical Patterns & Growth Focused Stock Pick Reports - newser.com
What analysts say about Cardiff Oncology Inc stockFlag and Pennant Patterns & Grow Smarter With Pro-Level Research - earlytimes.in
Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses - simplywall.st
What does recent volatility data suggest for Cardiff Oncology Inc.Market Trend Review & Fast Exit Strategy with Risk Control - newser.com
Will Cardiff Oncology Inc. (XE7C) stock beat international competitionEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Can Cardiff Oncology Inc. hit a new high this monthJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Will Cardiff Oncology Inc. stock gain from strong economyWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Using Bollinger Bands to evaluate Cardiff Oncology Inc.Entry Point & Verified Short-Term Plans - newser.com
Will Cardiff Oncology Inc. (XE7C) stock draw ESG focused fundsPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Is Cardiff Oncology Inc. stock a safe investment in uncertain marketsJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Should you hold or exit Cardiff Oncology Inc. now2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Can Cardiff Oncology Inc. (XE7C) stock sustain breakout momentumRecession Risk & Fast Moving Stock Watchlists - newser.com
Is Cardiff Oncology Inc. reversing from oversold territory2025 Trade Ideas & High Win Rate Trade Tips - newser.com
How Cardiff Oncology Inc. (XE7C) stock reacts to stronger dollarJuly 2025 Price Swings & Short-Term Swing Trade Alerts - newser.com
How Cardiff Oncology Inc. stock performs in rate cut cyclesJuly 2025 Sector Moves & Low Volatility Stock Recommendations - newser.com
Will Cardiff Oncology Inc. (XE7C) stock beat value stocksMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
Chart overlay techniques for tracking Cardiff Oncology Inc.2025 Stock Rankings & Expert Curated Trade Setups - newser.com
Can Cardiff Oncology Inc. (XE7C) stock double in coming yearsGold Moves & Low Risk High Reward Trade Ideas - newser.com
What is the fair value of Cardiff Oncology Inc. stock nowTrade Exit Report & Safe Entry Zone Identification - newser.com
Will Cardiff Oncology Inc. stock gain from lower inflation2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Can Cardiff Oncology Inc. (XE7C) stock stage a strong rebound this quarterQuarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Why retail traders accumulate Cardiff Oncology Inc. (XE7C) stockTrade Risk Assessment & Stock Portfolio Risk Management - Fundação Cultural do Pará
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):